Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SR9009 (Stenabolic) 是一种REV-ERBα/β激动剂,可增加由 REV-ERBα/ERBβ 调节的基因的组成性抑制,IC50分别为 670 nM 和 800 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 219 | 现货 | ||
2 mg | ¥ 333 | 现货 | ||
5 mg | ¥ 598 | 现货 | ||
10 mg | ¥ 842 | 现货 | ||
25 mg | ¥ 1,310 | 现货 | ||
50 mg | ¥ 2,420 | 现货 | ||
100 mg | ¥ 3,990 | 现货 | ||
500 mg | ¥ 8,750 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 718 | 现货 |
产品描述 | SR9009 (Stenabolic), a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes in the liver, skeletal muscle, and adipose tissue was also altered in mice exposed to SR9009, resulting in increased energy expenditure. In Diet-induced obese mice, SR9009 (100 mg/kg, i.p., b.i.d., for 30 days) could decrease fat mass and markedly improve dyslipidemia and hyperglycemia. |
靶点活性 | Rev-Erbα:670 nM, Rev-Erbβ:800 nM |
体外活性 | SR9009 effectively inhibits transcription in a cotransfection assay using full-length REV-ERBα along with a luciferase reporter driven by the Bmal1 promoter (SR9009 IC50: 710 nM). SR9009 suppresses the expression of BMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner. |
体内活性 | SR9009 inhibits the activity of the SCN clock, with reversible inhibition of circadian oscillations in SCN explants cultured from the Per2: Luc reporter mouse. |
细胞实验 | SR9009 is dissolved in DMSO and diluted with appropriate media[1]. HEK293 cells are grown in 96-well plates (1×106/well) and are transiently transfected using Lipofectamine. Cells are transfected with a total of 200 ng of DNA per well consisting of the pGL4 mIL-17 firefly luciferase reporter construct, the pGL4 mIL-17 + CNS-5 firefly luciferase reporter construct, or the pGL4 mIL-17 2kB RORE mutant (100 ng/well) , an actin promoter Renilla reniformis luciferase reporter (50 ng/well), and either control vector alone or the test DNA (full-length RORα or full-length RORγ at 50 ng/well). All 48 human nuclear receptors are represented in the specificity assay and SR9009 is tested at a concentration of 20 μM. The format of the assay is a cotransfection assay with Gal4 DNA binding domain-nuclear receptor fusions in HEK293 cells[1]. |
别名 | Stenabolic, REV-ERB Agonist II |
分子量 | 437.94 |
分子式 | C20H24ClN3O4S |
CAS No. | 1379686-30-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 43.8 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2834 mL | 11.4171 mL | 22.8342 mL | 57.0854 mL |
5 mM | 0.4567 mL | 2.2834 mL | 4.5668 mL | 11.4171 mL | |
10 mM | 0.2283 mL | 1.1417 mL | 2.2834 mL | 5.7085 mL | |
20 mM | 0.1142 mL | 0.5709 mL | 1.1417 mL | 2.8543 mL | |
50 mM | 0.0457 mL | 0.2283 mL | 0.4567 mL | 1.1417 mL | |
100 mM | 0.0228 mL | 0.1142 mL | 0.2283 mL | 0.5709 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SR9009 1379686-30-2 Autophagy Inhibitor inhibit Stenabolic SR 9009 REV-ERB Agonist II SR-9009 inhibitor